Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
- 25 February 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 8 (8), 775-785
- https://doi.org/10.1016/s2213-2600(19)30471-0
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Measuring cough severity: development and pilot testing of a new seven-item cough severity patient-reported outcome measureTherapeutic Advances in Respiratory Disease, 2010
- Measuring cough severity: Perspectives from the literature and from patients with chronic coughCough, 2009
- How to quantify coughing: correlations with quality of life in chronic coughEuropean Respiratory Journal, 2008
- Chronic cough: how do cough reflex sensitivity and subjective assessments correlate with objective cough counts during ambulatory monitoring?Thorax, 2007
- Chronic Cough From the Patient's PerspectiveMayo Clinic Proceedings, 2007
- Effectiveness of Amitriptyline Versus Cough Suppressants in the Treatment of Chronic Cough Resulting From Postviral Vagal NeuropathyThe Laryngoscope, 2006
- Recommendations for the management of cough in adultsThorax, 2006
- The New “Face” of CHEST Heralds a New EraSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- ATP Signaling Is Crucial for Communication from Taste Buds to Gustatory NervesScience, 2005
- Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)Thorax, 2003